全文获取类型
| 收费全文 | 1501665篇 |
| 免费 | 101927篇 |
| 国内免费 | 1746篇 |
专业分类
| 耳鼻咽喉 | 18203篇 |
| 儿科学 | 49858篇 |
| 妇产科学 | 39515篇 |
| 基础医学 | 215632篇 |
| 口腔科学 | 37176篇 |
| 临床医学 | 137005篇 |
| 内科学 | 290002篇 |
| 皮肤病学 | 29063篇 |
| 神经病学 | 124202篇 |
| 特种医学 | 57314篇 |
| 外国民族医学 | 265篇 |
| 外科学 | 216932篇 |
| 综合类 | 29067篇 |
| 现状与发展 | 4篇 |
| 一般理论 | 677篇 |
| 预防医学 | 129760篇 |
| 眼科学 | 31867篇 |
| 药学 | 106223篇 |
| 7篇 | |
| 中国医学 | 2725篇 |
| 肿瘤学 | 89841篇 |
出版年
| 2021年 | 10995篇 |
| 2019年 | 11683篇 |
| 2018年 | 37232篇 |
| 2017年 | 29391篇 |
| 2016年 | 33590篇 |
| 2015年 | 15517篇 |
| 2014年 | 20989篇 |
| 2013年 | 31179篇 |
| 2012年 | 48703篇 |
| 2011年 | 65473篇 |
| 2010年 | 43825篇 |
| 2009年 | 36112篇 |
| 2008年 | 61896篇 |
| 2007年 | 67689篇 |
| 2006年 | 43844篇 |
| 2005年 | 44835篇 |
| 2004年 | 44572篇 |
| 2003年 | 44379篇 |
| 2002年 | 40763篇 |
| 2001年 | 57052篇 |
| 2000年 | 58334篇 |
| 1999年 | 48905篇 |
| 1998年 | 14100篇 |
| 1997年 | 12928篇 |
| 1996年 | 13133篇 |
| 1995年 | 12368篇 |
| 1994年 | 11540篇 |
| 1992年 | 38646篇 |
| 1991年 | 38125篇 |
| 1990年 | 36918篇 |
| 1989年 | 35649篇 |
| 1988年 | 33069篇 |
| 1987年 | 32370篇 |
| 1986年 | 30833篇 |
| 1985年 | 29104篇 |
| 1984年 | 22212篇 |
| 1983年 | 19429篇 |
| 1982年 | 11612篇 |
| 1979年 | 21193篇 |
| 1978年 | 15586篇 |
| 1977年 | 12911篇 |
| 1976年 | 12018篇 |
| 1975年 | 12905篇 |
| 1974年 | 15722篇 |
| 1973年 | 15469篇 |
| 1972年 | 14597篇 |
| 1971年 | 13626篇 |
| 1970年 | 12874篇 |
| 1969年 | 12143篇 |
| 1968年 | 11313篇 |
排序方式： 共有10000条查询结果，搜索用时 855 毫秒
31.
Stepanova E. S. Makarenkova L. M. Chistyakov V. V. Rybakov Yu. L. Gukasov V. M. Fedotcheva T. A. Parshin V. A. Votyakov V. A. Shimanovskii N. L. 《Pharmaceutical Chemistry Journal》2019,52(12):1016-1020
Pharmaceutical Chemistry Journal - An HPLC-MS method for simultaneous quantitative determination of a novel gestagenic pharmaceutical and two of its metabolites in rat and rabbit blood sera was... 相似文献
32.
M.F. Werner A. López-Rueda F.X. Zarco J. Blasco L. San Román S. Amaro E. Carrero R. Valero L. Oleaga J.M. Macho N. Bargalló 《Radiologia》2019,61(2):143-152
Purpose
Endovascular treatment with mechanical thrombectomy devices demonstrated high recanalization rates but functional outcome did not correlate with high rates of recanalization obtained. Patient selection prior to the endovascular treatment is very important in the final outcome of the patient. The primary aim of our study was to evaluate the prognostic value of posterior circulation Alberta Stroke Program Early CT Score (pc-ASPECTS) and Pons-Midbrain Index (PMI) scores in patients with Basilar Artery Occlusion (BAO) treated with successful angiographic recanalization after mechanical thrombectomy.Methods
Retrospective single-center study including 18 patients between 2008 and 2013 who had acute basilar artery occlusion managed with endovascular treatment within 24 hours from symptoms onset and with successful angiographic recanalization. The patients were initially classified into two groups according to clinical outcome and mortality at 90 days. For analysis we also divided patients into groups based on pc-ASPECTS (≥8vs.< 8) and PMI (≥3vs.< 3) on non-contrast CT (NCCT) and CT Angiography Source Images (CTASI). Imaging data were correlated to clinical outcome and mortality rate.Results
CTASI pc-ASPECTS, dichotomized at < 8 versus≥8, was associated with a favorable outcome (RR: 2.6; 95% CI: 1.3-5.2) and a reduced risk of death (RR: 6.5: 95% CI: 7.8-23.3). All patients that survived and were functionally independent had pc-ASPECTS score≥8. None of the 5 patients with CTASI pc-ASPECTS score less than 8 survived.Conclusion
PC-ASPECTS on CTASI is helpful for predicting functional outcome after BAO recanalization with endovascular treatment. These results should be validated in a randomized controlled trial in order to decide whether or not to treat a patient with BAO. 相似文献33.
Novozhilov A. V. Mindukshev I. V. Korf E. A. Krivchenko A. I. Goncharov N. V. 《Bulletin of experimental biology and medicine》2020,168(4):444-448
Bulletin of Experimental Biology and Medicine - Ammonium, an end-product of catabolism, in low doses can promote adaptation of metabolic pathways in erythrocytes under conditions of extreme... 相似文献
34.
35.
Jennifer Weiss Ashley Glode Wells A. Messersmith 《Expert review of anticancer therapy》2019,19(8):673-679
Introduction: Triple negative breast cancer (TNBC) is an aggressive breast cancer subtype associated with an increased risk of recurrence and cancer-related death. Unlike hormone receptor-positive or HER2-positive breast cancers, there are limited targeted therapies available to treat TNBC and cytotoxic chemotherapy remains the mainstay of treatment. Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate targeting Trop-2 expressing cells and selectively delivering SN-38, an active metabolite of irinotecan.
Areas covered: This review covers the mechanism of action, safety and efficacy of sacituzumab govitecan in patients with previously treated, metastatic TNBC. Additionally, efficacy data in other epithelial malignancies is included based on a PubMed search for ‘sacituzumab govitecan’ and ‘clinical trial’.
Expert opinion: Sacituzumab govitecan has promising anti-cancer activity in patients with metastatic TNBC previously treated with at least two prior lines of systemic therapy based on a single arm Phase I/II clinical trial. A confirmatory Phase III randomized clinical trial is ongoing. Sacituzumab govitecan has a manageable side effect profile, with the most common adverse events being nausea, neutropenia, and diarrhea. The activity of sacituzumab govitecan likely extends beyond TNBC with promising early efficacy data in many other epithelial cancers, including hormone receptor-positive breast cancer. 相似文献
36.
Elizabeth D. Krebs Robert B. Hawkins J. Hunter Mehaffey Clifford E. Fonner Alan M. Speir Mohammed A. Quader Jeffrey B. Rich Leora T. Yarboro Nicholas R. Teman Gorav Ailawadi 《The Journal of thoracic and cardiovascular surgery》2019,157(4):1533-1542.e2
Objectives
Expedient extubation after cardiac surgery has been associated with improved outcomes, leading to postoperative extubation frequently during overnight hours. However, recent evidence in a mixed medical-surgical intensive care unit population demonstrated worse outcomes with overnight extubation. This study investigated the impact of overnight extubation in a statewide, multicenter Society of Thoracic Surgeons database.Methods
Records from 39,812 patients undergoing coronary artery bypass grafting or valve operations (2008-2016) and extubated within 24 hours were stratified according to extubation time between 06:00 and 18:00 (day) or between 18:00 and 6:00 (overnight). Outcomes including reintubation, mortality, and composite morbidity-mortality were evaluated using hierarchical regression models adjusted for Society of Thoracic Surgeons predictive risk scores. To further analyze extubation during the night, a subanalysis stratified patients into 3 groups: 06:00 to 18:00, 18:00 to 24:00, and 24:00 to 06:00.Results
A total of 20,758 patients were extubated overnight (52.1%) and were slightly older (median age 66 vs 65 years, P < .001) with a longer duration of ventilation (4 vs 7 hours, P < .001). Day and overnight extubation were associated with equivalent operative mortality (1.7% vs 1.7%, P = .880), reintubation (3.7% vs 3.4%, P = .141), and composite morbidity-mortality (8.2% vs 8.0%, P = .314). After risk adjustment, overnight extubation was not associated with any difference in reintubation, mortality, or composite morbidity-mortality. On subanalysis, those extubated between 24:00 and 06:00 exhibited increased composite morbidity-mortality (odds ratio, 1.18; P = .001) but no difference in reintubation or mortality.Conclusions
Extubation overnight was not associated with increased mortality or reintubation. These results suggest that in the appropriate clinical setting, it is safe to routinely extubate cardiac surgery patients overnight. 相似文献37.
38.
Whitney S. Brandt Wanpu Yan Jian Zhou Kay See Tan Joseph Montecalvo Bernard J. Park Prasad S. Adusumilli James Huang Matthew J. Bott Valerie W. Rusch Daniela Molena William D. Travis Mark G. Kris Jamie E. Chaft David R. Jones 《The Journal of thoracic and cardiovascular surgery》2019,157(2):743-753.e3
Objective
Comparative survival between neoadjuvant chemotherapy and adjuvant chemotherapy for patients with cT2-4N0-1M0 non–small cell lung cancer has not been extensively studied.Methods
Patients with cT2-4N0-1M0 non–small cell lung cancer who received platinum-based chemotherapy were retrospectively identified. Exclusion criteria included stage IV disease, induction radiotherapy, and targeted therapy. The primary end point was disease-free survival. Secondary end points were overall survival, chemotherapy tolerance, and ability of Response Evaluation Criteria In Solid Tumors response to predict survival. Survival was estimated using the Kaplan–Meier method, compared using the log-rank test and Cox proportional hazards models, and stratified using matched pairs after propensity score matching.Results
In total, 330 patients met the inclusion criteria (n = 92/group after propensity-score matching; median follow-up, 42 months). Five-year disease-free survival was 49% (95% confidence interval, 39-61) for neoadjuvant chemotherapy versus 48% (95% confidence interval, 38-61) for adjuvant chemotherapy (P = .70). On multivariable analysis, disease-free survival was not associated with neoadjuvant chemotherapy or adjuvant chemotherapy (hazard ratio, 1.1; 95% confidence interval, 0.64-1.90; P = .737), nor was overall survival (hazard ratio, 1.21; 95% confidence interval, 0.63-2.30; P = .572). The neoadjuvant chemotherapy group was more likely to receive full doses and cycles of chemotherapy (P = .014/0.005) and had fewer grade 3 or greater toxicities (P = .001). Response Evaluation Criteria In Solid Tumors response to neoadjuvant chemotherapy was associated with disease-free survival (P = .035); 15% of patients receiving neoadjuvant chemotherapy (14/92) had a major pathologic response.Conclusions
Timing of chemotherapy, before or after surgery, is not associated with an improvement in overall or disease-free survival among patients with cT2-4N0-1M0 non–small cell lung cancer who undergo complete surgical resection. 相似文献39.
40.
Nicholas E. Anton Tomoko Mizota Lava R. Timsina Jake A. Whiteside Erinn M. Myers Dimitrios Stefanidis 《American journal of surgery》2019,217(2):266-271